Introduction: Tension headache has become a major health problem for medical students. This can trigger a worsening in the quality of life of the student and hinder their learning, corroborating for an impaired education. Better understanding of the topic is necessary so the academics can have a better overview of the problem. Objective: Clarify the relationship between tension headache and the quality of life of medical students. Methods: Articles from the last ten years were selected on the Scielo and Google Scholar portal platforms, which made it possible through an online scenario. Results: The mechanisms of tension headache are controversial and their pathophysiology complex and poorly understood. In crises, analgesics, antiinflammatories, muscle relaxants and/or caffeine are applied. In the articles studied, epidemiological data suggest that most students (99%) have already had a headache case during their lifetime and such occurrences are related to moments of stress and tiredness (74%). It is visible, that the academic affected by various activities, is a target for the disease. Conclusion: The prevalence of tension headache in the medical student was higher than that of the general population, with stress as the main reason. then a resolution on the issue of pain regarding stress is necessary since it proved to be inappropriate.
Introduction: Huntington’s disease (HD) is a congenital pathology of a hereditary, neurodegenerative and progressive character, with a high mortality rate. This pathology is caused by repeated expansions of a single CAG codon in the gene encoding huntingtin. To date, several attempts to prevent and delay such a mutation have been carried out in patients. However, a promising drug, Tominersen, formerly called IONIS HTTRx/ RG6042, is in the testing phase and has shown a favorable therapeutic response, which acts directly on the messenger RNA of the gene encoding huntingtin (HTT). The drug, whose route of administration is intrathecal in bolus, intercepts and destroys the messenger before the corrupted protein can work. The present study aims to analyze the impact of Tominersen in the treatment of patients with HD and to evaluate its prognosis. Methods: The present study is a systematic literature review, in which an electronic search was performed in the PubMed, SciELO, Web of Science and Google Scholar databases. Results: In one of the double-blind randomized clinical trials (n = 46), 34 were assigned to receive the drug. The group that received Tominersen showed a decrease in the concentration of mutant HTT in cerebrospinal fluid after 28 days. In another study (n = 791), the GENERATION HD1 clinical trial is currently taking place and will last for 25 months. Conclusion: Tominersen decreases the concentration of HTT, that is, it suppressed the protein responsible for HD. Studies related to the drug are still very recent and require extra attention.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.